Fig. 3From: Production and characterization of no-carrier-added 161Tb as an alternative to the clinically-applied 177Lu for radionuclide therapyGamma spectrum of 161Tb, obtained after the purification process. The radionuclidic impurity 160Tb is not visible due to the negligible activity as compared to that of 161Tb at end of separation (EOS)Back to article page